Xu S - Search Results

1

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K. Hu J, et al. Among authors: xu s, xu d. Mol Cancer Ther. 2013 Sep;12(9):1763-73. doi: 10.1158/1535-7163.MCT-13-0123. Epub 2013 Jul 5. Mol Cancer Ther. 2013. PMID: 23832122

2

Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.

Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Xu S, et al. Stem Cells. 2012 Feb;30(2):266-79. doi: 10.1002/stem.787. Stem Cells. 2012. PMID: 22102554

3

Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.

De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E, Van Riet I. De Veirman K, et al. Among authors: xu s. Cancer Lett. 2016 Jul 10;377(1):17-24. doi: 10.1016/j.canlet.2016.04.024. Epub 2016 Apr 19. Cancer Lett. 2016. PMID: 27102001

4

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Xu S, et al. PLoS One. 2013 Nov 6;8(11):e79752. doi: 10.1371/journal.pone.0079752. eCollection 2013. PLoS One. 2013. PMID: 24223191 Free PMC article.

5

Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?

Xu S, De Veirman K, De Becker A, Vanderkerken K, Van Riet I. Xu S, et al. Leukemia. 2018 Jul;32(7):1500-1514. doi: 10.1038/s41375-018-0061-9. Epub 2018 Feb 22. Leukemia. 2018. PMID: 29535427 Free PMC article. Review.

6

An improved harvest and in vitro expansion protocol for murine bone marrow-derived mesenchymal stem cells.

Xu S, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Xu S, et al. J Biomed Biotechnol. 2010;2010:105940. doi: 10.1155/2010/105940. Epub 2010 Dec 20. J Biomed Biotechnol. 2010. PMID: 21197440 Free PMC article.

7

In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.

Xu S, De Becker A, De Raeve H, Van Camp B, Vanderkerken K, Van Riet I. Xu S, et al. Biochem Biophys Res Commun. 2012 Aug 3;424(3):391-7. doi: 10.1016/j.bbrc.2012.06.118. Epub 2012 Jul 6. Biochem Biophys Res Commun. 2012. PMID: 22771324

8

Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.

Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K, Van Riet I. Xu S, et al. Acta Pharmacol Sin. 2013 May;34(5):699-709. doi: 10.1038/aps.2012.182. Epub 2013 Apr 8. Acta Pharmacol Sin. 2013. PMID: 23564084 Free PMC article.

9

Vorinostat-induced bone loss might be related to drug toxicity.

Xu S, De Veirman K, Vanderkerken K, Van Riet I. Xu S, et al. Bone. 2013 Dec;57(2):384-5. doi: 10.1016/j.bone.2013.08.024. Epub 2013 Aug 30. Bone. 2013. PMID: 23999199 No abstract available.

10

Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation.

Xu D, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B, Vanderkerken K, Van Valckenborgh E. Xu D, et al. Among authors: xu s. Leukemia. 2012 Jun;26(6):1402-5. doi: 10.1038/leu.2011.332. Epub 2011 Nov 18. Leukemia. 2012. PMID: 22094583 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27,242 results

Search Page

Filters